Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Distribution and Chemotactic Mechanism of CD4+ T Cells in Traumatic Tracheal Stenosis
  • +2
  • tingmei feng,
  • yan chen,
  • jinmei wei,
  • sen tan,
  • liu guangnan
tingmei feng
The Second Affiliated Hospital of Guangxi Medical University
Author Profile
yan chen
The Second Affiliated Hospital of Guangxi Medical University
Author Profile
jinmei wei
The Second Affiliated Hospital of Guangxi Medical University
Author Profile
sen tan
The Second Affiliated Hospital of Guangxi Medical University
Author Profile
liu guangnan
The Second Affiliated Hospital of Guangxi Medical University

Corresponding Author:[email protected]

Author Profile

Abstract

Abstract: A systemic and local inflammatory immune imbalance is thought to be the cause of traumatic tracheal stenosis (TS). However, with CD4+ T lymphocytes being the predominant immune cells in TS, the mechanism of action and recruitment has not been described. In our research, using flow cytometry, ELISA, immunofluorescence, and Transwell chamber assays, the expression, distribution, and potential chemotactic function of CD4+ T cells in TS patients were examined before and after treatment. The results showed that the untreated group had significantly more CD4+ T cells and their secreted TGF-β1 than the treated group. Additionally, the untreated group’s CD4+ T cells showed a significant rise in CCL22 and CCL1, as well as a larger proportion of CCR4 and CCR8. CD4+ T cells and CD68+ macrophages located in TS also expressed CCL1 and CCL22. In vitro, anti-CCL1 and anti-CCL22 can partially block the chemoattractant effect of TS bronchoalveolar lavage (BAL) on purified CD4+ T cells. The findings of this study indicated that TS contained unbalanced CD4 immune cells that were actively recruited locally by CCR4/CCL22 and CCR8/CCL1. As a result, it is anticipated that CD4 immune rebalancing can serve as a novel treatment for TS.
09 Jan 2023Submitted to Immunity, Inflammation and Disease
13 Jan 2023Submission Checks Completed
13 Jan 2023Assigned to Editor
13 Jan 2023Review(s) Completed, Editorial Evaluation Pending
26 Jan 2023Reviewer(s) Assigned
27 Apr 2023Editorial Decision: Revise Major
31 May 20231st Revision Received
31 May 2023Submission Checks Completed
31 May 2023Assigned to Editor
31 May 2023Review(s) Completed, Editorial Evaluation Pending
31 May 2023Reviewer(s) Assigned
01 Jun 2023Editorial Decision: Accept
Aug 2023Published in Immunity, Inflammation and Disease volume 11 issue 8. https://doi.org/10.1002/iid3.916